WO2010034105A8 - Hepatitis c inhibitor compounds - Google Patents
Hepatitis c inhibitor compounds Download PDFInfo
- Publication number
- WO2010034105A8 WO2010034105A8 PCT/CA2009/001237 CA2009001237W WO2010034105A8 WO 2010034105 A8 WO2010034105 A8 WO 2010034105A8 CA 2009001237 W CA2009001237 W CA 2009001237W WO 2010034105 A8 WO2010034105 A8 WO 2010034105A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepatitis
- inhibitor compounds
- analogs
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2737958A CA2737958A1 (en) | 2008-09-23 | 2009-09-14 | Hepatitis c inhibitor compounds |
EP09815517A EP2344487A4 (en) | 2008-09-23 | 2009-09-14 | Hepatitis c inhibitor compounds |
JP2011527161A JP2012502925A (en) | 2008-09-23 | 2009-09-14 | Hepatitis C inhibitor compound |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9929208P | 2008-09-23 | 2008-09-23 | |
US61/099,292 | 2008-09-23 | ||
US18663209P | 2009-06-12 | 2009-06-12 | |
US61/186,632 | 2009-06-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010034105A1 WO2010034105A1 (en) | 2010-04-01 |
WO2010034105A8 true WO2010034105A8 (en) | 2011-01-06 |
Family
ID=42059237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2009/001237 WO2010034105A1 (en) | 2008-09-23 | 2009-09-14 | Hepatitis c inhibitor compounds |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2344487A4 (en) |
JP (1) | JP2012502925A (en) |
AR (1) | AR073659A1 (en) |
CA (1) | CA2737958A1 (en) |
TW (1) | TW201016694A (en) |
WO (1) | WO2010034105A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
JP2012505897A (en) * | 2008-10-15 | 2012-03-08 | インターミューン・インコーポレーテッド | Antiviral peptide for treatment |
CN103534256B (en) | 2010-12-30 | 2016-08-10 | 益安药业 | Macrocyclic hepatitis c serine protease inhibitors |
PE20140039A1 (en) | 2010-12-30 | 2014-03-01 | Enanta Pharm Inc | HEPATITIS C SERINE PROTEASE INHIBITORS BASED ON Phenanthridine Macrocyclics |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
LT2909205T (en) | 2012-10-19 | 2016-12-27 | Bristol-Myers Squibb Company | 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
EA009295B1 (en) * | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Hepatitis c inhibitor compounds |
US7514557B2 (en) * | 2004-05-25 | 2009-04-07 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic HCV protease inhibitors |
WO2006000085A1 (en) * | 2004-06-28 | 2006-01-05 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
KR101596524B1 (en) * | 2007-06-29 | 2016-02-22 | 길리애드 사이언시즈, 인코포레이티드 | Antiviral compound |
EA200971074A1 (en) * | 2007-06-29 | 2010-08-30 | Джилид Сайэнс, Инк. | ANTI-VIRUS CONNECTIONS |
JP5529036B2 (en) * | 2007-12-05 | 2014-06-25 | エナンタ ファーマシューティカルズ インコーポレイテッド | Fluorinated tripeptide HCV serine protease inhibitor |
-
2009
- 2009-09-14 CA CA2737958A patent/CA2737958A1/en not_active Abandoned
- 2009-09-14 JP JP2011527161A patent/JP2012502925A/en active Pending
- 2009-09-14 WO PCT/CA2009/001237 patent/WO2010034105A1/en active Application Filing
- 2009-09-14 EP EP09815517A patent/EP2344487A4/en not_active Withdrawn
- 2009-09-22 AR ARP090103651A patent/AR073659A1/en unknown
- 2009-09-22 TW TW098131961A patent/TW201016694A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CA2737958A1 (en) | 2010-04-01 |
WO2010034105A1 (en) | 2010-04-01 |
EP2344487A4 (en) | 2012-03-21 |
JP2012502925A (en) | 2012-02-02 |
AR073659A1 (en) | 2010-11-24 |
EP2344487A1 (en) | 2011-07-20 |
TW201016694A (en) | 2010-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010034105A8 (en) | Hepatitis c inhibitor compounds | |
MY164469A (en) | Hcv ns3 protease inhibitors | |
WO2008021936A3 (en) | Hepatitis c virus inhibitors | |
WO2008057208A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051514A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051475A3 (en) | Hcv ns3 protease inhibitors | |
UA83046C2 (en) | Hepatitis c inhibitor compounds, pharmaceutical composition based thereon | |
EP1924593B8 (en) | Hcv ns3 protease inhibitors | |
WO2008057995A3 (en) | Hcv protease inhibitors | |
WO2008021927A3 (en) | Hepatitis c virus inhibitors | |
MX2009009174A (en) | Inhibitors of serine proteases for the treatment of hcv infections. | |
WO2008051477A3 (en) | Hcv ns3 protease inhibitors | |
WO2006119061A3 (en) | Hcv ns3 protease inhibitors | |
MY159958A (en) | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors | |
IL196815A0 (en) | Hepatitis c virus inhibitors | |
WO2007008657A3 (en) | Hepatitis c virus inhibitors | |
MY152070A (en) | Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors | |
IL198741A0 (en) | Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof | |
NO20091845L (en) | Macrocyclic peptides such as hepatitis C virus inhibitors | |
MX2011009644A (en) | Hepatitis c virus inhibitors. | |
BR112012011100A2 (en) | hepatitis virus inhibitor compounds, composition and use thereof | |
WO2008057871A3 (en) | Inhibitors of hepatitis c virus | |
MX2011006631A (en) | Hcv ns3 protease inhibitors. | |
WO2008057875A3 (en) | Inhibitors of hepatitis c virus | |
WO2004032827A3 (en) | Hepatitis c virus inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09815517 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase in: |
Ref document number: 2011527161 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2737958 Country of ref document: CA |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009815517 Country of ref document: EP |